Microsatellite instability and loss of heterozygosity in prostatic carcinomas: Comparison of primary tumors, and of corresponding recurrences after androgen-deprivation therapy and lymph-node metastases

Citation
H. Rohrbach et al., Microsatellite instability and loss of heterozygosity in prostatic carcinomas: Comparison of primary tumors, and of corresponding recurrences after androgen-deprivation therapy and lymph-node metastases, PROSTATE, 40(1), 1999, pp. 20-27
Citations number
38
Categorie Soggetti
Urology & Nephrology","da verificare
Journal title
PROSTATE
ISSN journal
02704137 → ACNP
Volume
40
Issue
1
Year of publication
1999
Pages
20 - 27
Database
ISI
SICI code
0270-4137(19990615)40:1<20:MIALOH>2.0.ZU;2-6
Abstract
BACKGROUND. The molecular mechanisms leading to prostate cancer progression are poorly understood. In particular, those changes which are responsible for androgen-independent growth and metastatic spread in prostate cancer ar e an issue of current investigations. METHODS. To gain more insight into these processes, paired microdissected s amples from both untreated, locally advanced primary tumors (n = 20) and re currences (n = 20) after conventional androgen-deprivation therapy (ADT) we re analyzed retrospectively for microsatellite instability (MSI) and loss o f heterozygosity (LOH) at nine loci on chromosomes 8, 18, and X by polymera se chain reaction. In parallel, 12 prostatic carcinomas treated by radical prostatectomy and nine corresponding lymph-node metastases were analyzed in the same way. RESULTS. The group treated with ADT showed a total of 10 MSI in 7 of the pr imary tumors (35%): 4 of these (20%) at one locus, and 3 of these (15%) at two loci. In the recurrences, MSI was observed in 4 cases (20%): 3 of these at one locus (15%), and 1 of these (5%) at two loci. LOH was found in 8 ca ses (40%) before as well as after ADT. In the radically resected carcinomas , MSI could be detected at two chromosomal loci in one of the primary tumor s (8%) and in one of the metastases (11%); LOH was found in 2 primaries (16 %) and 3 metastases (33%). CONCLUSIONS. Although MSI can be found in advanced prostatic carcinomas, it apparently does not play a major role in the progression of prostate cance r regarding androgen-independent growth or lymphogenous spread. (C) 1999 Wi ley-Liss, Inc.